<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To evaluate the efficacy and safety of initial combination therapy with linagliptin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> versus linagliptin or <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In this 24-week, double-blind, placebo-controlled, Phase III trial, 791 patients were randomized to one of six treatment arms </plain></SENT>
<SENT sid="2" pm="."><plain>Two free combination therapy arms received linagliptin 2.5 mg twice daily (bid) + either low (500 mg) or high (1000 mg) dose <z:chebi fb="0" ids="6801">metformin</z:chebi> bid </plain></SENT>
<SENT sid="3" pm="."><plain>Four monotherapy arms received linagliptin 5 mg once daily, <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg or 1000 mg bid or placebo </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) â‰¥11.0% were not eligible for randomization and received open-label linagliptin + high-dose <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The placebo-corrected mean (95% confidence interval) change in HbA1c from baseline (8.7%) to week 24 was -1.7% (-2.0, -1.4) for linagliptin + high-dose <z:chebi fb="0" ids="6801">metformin</z:chebi>, -1.3% (-1.6, -1.1) for linagliptin + low-dose <z:chebi fb="0" ids="6801">metformin</z:chebi>, -1.2% (-1.5, -0.9) for high-dose <z:chebi fb="0" ids="6801">metformin</z:chebi>, -0.8% (-1.0, -0.5) for low-dose <z:chebi fb="0" ids="6801">metformin</z:chebi> and -0.6 (-0.9, -0.3) for linagliptin (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>In the open-label arm, the mean change in HbA1c from baseline (11.8%) was -3.7% </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> occurred at a similar low rate with linagliptin + <z:chebi fb="0" ids="6801">metformin</z:chebi> (1.7%) as with <z:chebi fb="0" ids="6801">metformin</z:chebi> alone (2.4%) </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse event rates were comparable across treatment arms </plain></SENT>
<SENT sid="9" pm="."><plain>No clinically significant changes in body weight were noted </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Initial combination therapy with linagliptin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> was superior to <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy in improving glycaemic control, with a similar safety and tolerability profile, no <z:mp ids='MP_0005456'>weight gain</z:mp> and a low risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
</text></document>